Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $360.76, for a total value of $3,607,600.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $929,678.52. The trade was a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Tuesday, February 18th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00.
• On Monday, February 10th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00.
• On Monday, February 3rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $353.64, for a total value of $3,536,400.00.
• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $356.68, for a total value of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $361.95, for a total value of $3,619,500.00.

United Therapeutics Stock Down 10.8 %

UTHR stock opened at $318.89 on Thursday. United Therapeutics Co. has a twelve month low of $221.53 and a twelve month high of $417.82. The stock has a market cap of $14.24 billion, a P/E ratio of 14.00, a PEG ratio of 0.97 and a beta of 0.57. The business’s 50-day moving average price is $361.17 and its 200-day moving average price is $360.81.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the previous year, the firm earned $4.36 EPS. On average, equities research analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics in the 4th quarter worth approximately $25,000. Brooklyn Investment Group purchased a new position in United Therapeutics in the 3rd quarter worth approximately $33,000. Dunhill Financial LLC lifted its holdings in United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 50 shares in the last quarter. State of Wyoming purchased a new position in United Therapeutics in the 4th quarter worth approximately $62,000. Finally, Millstone Evans Group LLC purchased a new position in United Therapeutics in the 4th quarter worth approximately $67,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the subject of a number of recent research reports. Oppenheimer boosted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. The Goldman Sachs Group boosted their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. HC Wainwright boosted their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, LADENBURG THALM/SH SH boosted their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.